25 research outputs found

    Corporate identity, customer orientation and performance of SMEs: Exploring the linkages

    Get PDF
    This research aims to explore the impact of corporate identity (CI) on performance in B2C small and medium enterprises (SMEs) in food processing, with varying degrees of customer orientation (CO). The research is embedded in the positivistic paradigm. Based on a literature review, a conceptual model (consisting of five hypotheses) has been tested with 102 samples using PLS-SEM tool. This study establishes the mediating role of CO on the CI and performance linkage, it provides empirical evidence to CI and performance linkage, and makes an incremental contribution by extension of theory of CI and CO in the given context

    Not Available

    No full text
    Not AvailableMolecular markers are useful tools for assaying genetic variation and provide an efficient means for early and reliable selection of genotypes having resistance to peanut bud necrosis disease (PBND) in peanut breeding programs. Molecular diversity and association of simple sequence repeat (SSR) markers with resistance to PBND was detected in 21 interspecific pre-breeding lines and three cultivars of peanut differing in degree of resistance to PBND. Forty-five primer pairs yielded a total of 531 fragments, of which 337 were polymorphic, with an average of 7.5 polymorphic fragments per primer. Polymorphism ranged from 0 - 100% with an average of 60.2%. Cluster analysis (UPGMA) revealed two main clusters separated at 77% Jaccard’s similarity oefficient based on resistance to PBND. All 14 susceptible lines were grouped into a single cluster, while 11 resistant lines grouped into a separate cluster. AMOVA among 24 lines detected 43% (P < 0.001) of total variation associated with resistance to PBND. Kruskal-Wallis ANOVA detected the significant association of 16 primers with resistance to PBND. Nine out of 16 primers explained more than 10% of phenotypic variation due to resistance to PBND. It appears that these loci are associated with the resistance to PBND in peanut and major QTLs with regression coefficient value (r2) ranging from 10.1% to 77.5%. Of which PM15190, PM188165 and PM201130 loci effectively differentiated most of the resistant lines from the susceptible lines.Not Availabl

    Homogeneous and polymorphic transformations to ordered intermetallics in nanostructured Au-Cu multilayer thin films

    No full text
    Atomic arrangements in the nanostructured grains and interfaces of thermally evaporated Au/Cu multilayer thin films on polycrystalline Si substrate have been explored through GIXRD, HRTEM, simulation, and direct structure imaging. GIXRD pattern conforms to cF4 solid solution of Au and Cu with peak broadening and shift. Comparative analysis with simulation indicated the presence of cP4, tP4, oP8, and oI40 phases in the multilayer. The Cu layer is amorphous. Localized amorphous phase forms at the Cu-Si interface due to the impingement of Cu atoms during deposition. Interfaces of Au-Cu are wavy. The Au layer is polycrystalline and columnar with some twin-like defects present in them. At the Cu-Au interface, diffusionally grown cP4, tP4, oI40, and oP8 phases could be observed. Adatom mobility, concurrent growth, and coalescence of growth islands lead to columnar growth. Ordered intermetallic phases could be related with the cF4 solid solution phase through polymorphism. The strain associated with the polymorphs and the solid solution phase is quite small. Faceted semi-coherent interfaces of the ordered phases with the solid solution phase have been resolved. The ordered phases grow into the solid solution matrix by homogeneous transformation. Structure imaging of the ordered phases indicated that most of the time a cluster of atoms is imaged in these structures. The interfaces are likely to be chemically diffused in nature. Polymorphism and homogeneous nature of the transformation at low temperature allows local transformation to ordered phases, that explain the phase field ambiguity in the binary phase diagram. Such structural details are critical in understanding the novel properties in these nanostructured alloys

    De-Novo drug design of novel 1,2,3–triazole-naphthamide as an inhibitor of SARS-Cov-2 main protease: Synthesis, bioinformatics and biophysical studies

    No full text
    1001-1011A novel 1,2,3-triazole-napthamide molecule (SSAM-1) is designed as per De-Novo drug design method and synthesized by using copper-catalyzed alkyne-azide cycloaddition reaction. The interaction studies of SSAM-1 with bovine serum albumin (BSA), human serum albumin (HSA) and bromelain (BMLN) are investigated by steady state fluorescence spectroscopic studies. The experimental results for these interaction studies are validated by molecular docking method. The theoretical prediction of ADMET properties of SSAM-1 are also performed using computational methods. All these studies indicate significant and spontaneous binding of SSAM-1 with serum albumins and BMLN at pH 7 under varying temperature conditions (288K, 298K, 308K). In all the three cases the interaction of the molecule with the proteins and enzymes led to quenching of the fluorescence emission (mainly via static quenching mechanism) of tryptophan (Trp) residue present in the proteins and in the enzyme. The complexation with SSAM-1 changes the microenvironment of the Trp residue(s) of BSA, HSA and BMLN. Strong binding affinity between proteins and SSAM-1 is indicated by the binding constant values, which is in 103-105 orders. Hydrophobic forces are acting as the major interacting forces for SSAM-1-HSA interaction while H-bonding and van der Waals forces are acting as the primary interacting forces for SSAM-1 interacting with BSA and BMLN. ADMET prediction reveals the drug-able nature of SSAM-1 which is justified due to its ability to bind with the serum albumins. In addition binding study of SSAM-1 with BMLN indicates its possibility of oral administration. Conducting such binding studies of the newly synthesized triazole with biomolecules, an effort is made to assess the contribution of a novel compound to the development of medicines for the drug design process at a very early stage of the research
    corecore